Drug Profile


Alternative Names: Kevetrin

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Cellceutix
  • Developer Cellceutix; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Nitriles; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; Caspase 3 stimulants; Poly(ADP-ribose) polymerase modulators; Retinoblastoma protein modulators; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Retinoblastoma; Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ovarian cancer

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours
  • Preclinical Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Glioblastoma; Head and neck cancer; Lung cancer; Lymphoma; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal cancer; Retinoblastoma

Most Recent Events

  • 03 Mar 2017 Interim pharmacokinetics, pharmacodynamics and adverse events data from a preclinical study in Cancer released by Cellceutix Corporation (PO)
  • 09 Feb 2017 Phase-II clinical trials in Ovarian cancer (Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03042702)
  • 15 Dec 2016 Preclinical trials in Ovarian cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top